Sort   by:  
 Page size 
GenomicsGenome-wide maps of H3K4me2/3 in prostate cancer cell line LNCaP
We report the high-throughput profiling of histone modifications in prostate cancer cells. By obtaining over 1 billion bases of sequence from chromatin immunoprecipitated DNA, we generated genome-wide chromatin-state maps of prostate cancer cells. we found androgen treatment dismisses a nucleosome o...
ORGANISM(S): Homo sapiens 
2010-03-09 | E-GEOD-20042 | biostudies-arrayexpress
TranscriptomicsMapping the C. elegans non-coding transcriptome with a whole genome tiling microarray
The number of annotated protein coding genes in the genome of Caenorhabditis elegans is similar to that of other animals, but the extent of its non-protein coding transcriptome remains unknown. Expression profiling on whole genome tiling microarrays applied to a mixed stage C. elegans population ver...
ORGANISM(S): Caenorhabditis elegans 
2007-09-06 | E-GEOD-8543 | biostudies-arrayexpress
GenomicsGenome-wide maps of AR binding in prostate cancer cell lines VCaP and VCS2
We report the high-throughput profiling of AR binding in prostate cancer cells. Examination of AR binding in prostate cancer cell lines VCaP and VCS2
ORGANISM(S): Homo sapiens 
2012-02-01 | E-GEOD-32345 | biostudies-arrayexpress
GenomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [Chem-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63284 | biostudies-arrayexpress
TranscriptomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [RNA-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63582 | biostudies-arrayexpress
GenomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [ChIP-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63581 | biostudies-arrayexpress
Sort   by:  
 Page size